

Kelly R. Peck, Ph.D.

## CURRICULUM VITAE

Position: Assistant Professor  
Department of Psychiatry

Address: 1423 University Health Center  
Department of Psychiatry  
The Robert Larner, M.D. College of Medicine  
University of Vermont  
Burlington, VT 05405  
Voice: (802) 656-9610  
email: Kelly.Peck@uvm.edu

### EDUCATION

<b>Year</b>	<b>Institution</b>	<b>Degree</b>	<b>Area of Degree, Accolades</b>
2007-2010	University of Memphis Memphis, TN	B.A.	Psychology, Magna Cum Laude
2011-2014	University of Mississippi Oxford, MS (Todd Smitherman, Ph.D.)	M.A.	Clinical Psychology Research: <i>Moderation and Mediation of Headache-Related Disability: The Roles of Self-Efficacy and Headache Diagnosis</i>
2011-2017	University of Mississippi Oxford, MS (Todd Smitherman, Ph.D.)	Ph.D.	Clinical Psychology Research: <i>Factors Associated with Medication-Overuse Headache in Patients Seeking Treatment for Primary Headache</i>
2016-2017	University of Mississippi Medical Center/G.V. (Sonny) Montgomery VAMC Jackson, MS (Scott Coffey, Ph.D.)	Clinical Psychology Predoctoral Internship	Clinical Psychology
2017-2019	University of Vermont Burlington, VT (Stacey Sigmon, Ph.D.)	NIH Postdoctoral Fellow	Behavioral Economics & Behavioral Pharmacology

**LICENSES, CERTIFICATION**

<b>Years</b>	<b>License/Certification</b>
2019-Present	Licensed Psychologist - Doctorate, State of Vermont

**FACULTY POSITIONS HELD**

<b>Years</b>	<b>Institution</b>	<b>Academic Title</b>	<b>Department</b>
2019-Present	University of Vermont	Assistant Professor	Psychiatry (primary) Psychological Science (secondary)

**OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD**

<b>Years</b>	<b>Location/Program Name</b>	<b>Role</b>
2019-Present	<b>Graduate College, University of Vermont</b> The Graduate College at the University of Vermont was formally established in 1952, though the first graduate degree had been awarded in 1807. The Graduate College includes programs and degrees in the natural, physical and biological sciences, the social sciences, the humanities, and professional training. Notably, many programs are interdisciplinary, especially in the biological and biomedical sciences as well as in environmental and ecological programs.	Faculty Member
2019-Present	<b>Vermont Center on Behavior and Health (P20 GM103644)</b> The Vermont Center on Behavior and Health (VCBH) was established in 2013 and is funded by a NIGMS Centers of Biomedical Research Excellence (COBRE) Award. The VCBH's participating investigators, collaborators, and advisors extend across 15 academic departments in the College of Medicine, 7 colleges within the University of Vermont and 5 additional universities. The focus of our center is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk and developing effective interventions and policies to promote healthy behavior. I serve as a Project Director for our COBRE center grant.	Project Director

**HONORS AND AWARDS**

<b>Year</b>	<b>Name of Award</b>
2011-2016	Graduate Research Fellowship, University of Mississippi
2012 & 2013	St. Jude Children's Research Hospital Student Travel Award
2013, 2015 & 2017	University of Mississippi Graduate Student Travel Award
2015	John and Lillian Wolfe Graduate Award for Excellence, University of Mississippi
2015	Graduate Achievement Award in Psychology, University of Mississippi
2017	University of Mississippi Medical Center Student Travel Award
2019	Director's Travel Award, National Institute on Drug Abuse

## **KEYWORDS/AREAS OF INTEREST**

Substance use disorders, opioids, buprenorphine, methadone, posttraumatic stress disorder, prolonged exposure therapy, anxiety disorders, chronic pain, adolescents, young adults

## **SUMMARY OF PROFESSIONAL ACTIVITIES- OVERALL**

I am an Assistant Research Professor in the department of Psychiatry in UVM's Larner College of Medicine, with a secondary appointment in UVM's Department of Psychological Science. After completing my postdoctoral fellowship, I joined the Psychiatry faculty in March of 2019 when I received a research grant from the National Institutes of General Medical Sciences. I am the Primary Investigator on this R21-equivalent project that is funded through a larger COBRE P20 award. This ongoing randomized trial is designed to investigate the contribution of prolonged exposure therapy for reducing posttraumatic stress disorder (PTSD) severity above and beyond opioid agonist therapy (OAT) alone for reducing PTSD symptomatology among adults with concurrent PTSD and opioid use disorder (OUD).

In addition to this programmatic research aimed at developing and evaluating cognitive-behavioral treatments for PTSD, I am currently coordinating two randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated OUD. As a result of these efforts, I have published 18 manuscripts in peer-reviewed scientific journals and present my research at numerous national and international scientific meetings annually. I have also co-authored chapters in 2 textbooks.

I am also dedicated to clinical and scientific service. Since joining the Vermont Center on Behavioral and Health (VCBH) as a post-doctoral fellow, I have provided evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic. I also obtained licensure as a clinical psychologist in Vermont in 2019.

As part of the UVM Larner College of Medicine's preparation for the LCME Accreditation process, I was also selected by the Department Chair to serve as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement. I have also been a member of The College on Problems of Drug Dependence (CPDD) since 2017, which is the oldest and largest organization dedicated to advancing the scientific study of substance use. During this time I have served CPDD as Travel Awards Committee member. Furthermore, I serve as an ad hoc reviewer for 10 journals.

Finally, since joining the VCBH research faculty, my role has involved training and supervising pre- and post-doctoral fellows as well as research project staff and therapists. I am the primary research mentor for a doctoral student as part of the UVM clinical psychology doctoral program. During the past year, I was also honored to serve for the first time as a member of a dissertation committee for a doctoral candidate in the clinical psychology program. As part of my post-doctoral training with Dr. Stacey Sigmon and my ongoing involvement with IBT trial, I have been fortunate to serve as a co-mentor to several pre-doctoral fellows. As a result, I published several recent papers as with VCBH pre- and post-doctoral fellows.

Overall, I have sought to maintain high levels of productivity in clinical research, clinical and scientific service, mentoring and teaching since joining the Department of Psychiatry faculty in 2019.

**SUMMARY OF ACCOMPLISHMENTS**

- \$487,541 in funding as PI
- 18 peer-reviewed articles (h-index=6)
- Primary research mentor for a doctoral student as part of the UVM clinical psychology doctoral program
- Awarded the University of Mississippi's John and Lillian Wolfe Graduate Award for Excellence and Graduate Achievement Award in Psychology in 2015
- Selected by the Department Chair to serve as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement in preparation for the LCME Accreditation process at the UVM Larner College of Medicine
- Served as a member of the Travel Awards Committee for the College on Problems of Drug Dependence (CPDD) since 2017
- Provide evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic
- Service as an ad hoc reviewer for 10 journals

**PROFESSIONAL SERVICE**

---

**DEPARTMENTAL SERVICE**

<b>Years</b>	<b>Department</b>		
2018-2019	Psychiatry/VCBH	Vermont Center on Behavior and Health Trainee Seminar	Organizer
2020-Present	Psychiatry/VCBH	Executive Committee, UVM Center of Biomedical Research Excellence (COBRE) at VCBH	Member

**COLLEGE SERVICE**

2020-2021	Sub-Committee 8 Curricular Management, Evaluation, and Enhancement in preparation for the LCME site accreditation visit.	Member
-----------	--	--------

**MEDICAL CENTER SERVICE**

Not applicable

**UNIVERSITY SERVICE**

Not applicable

**GOVERNMENT**

Not applicable

**SOCIETY MEMBERSHIPS**

2017 – Present	College on Problems of Drug Dependence (Member)
2018 – Present	Association of Behavioral and Cognitive Therapists (Member)
2019 – Present	American Psychological Association (Member)

2019 – Present American Psychological Association Division 28  
Psychopharmacology and Substance Abuse (Member)

### **SERVICE TO PROFESSIONAL ORGANIZATIONS**

2017-Present	College on Problems of Drug Dependence	Member, Travel Awards Committee
--------------	--	---------------------------------

### **SERVICE TO PROFESSIONAL PUBLICATIONS**

Not applicable

### **PUBLIC SERVICE**

Not applicable

### **OTHER**

**Ad hoc reviewer for 10 journals, including:** *American Journal of Preventive Medicine, Applied Psychophysiology and Biofeedback, Drug and Alcohol Dependence, Headache, International Journal of Behavioral Medicine, Journal of Addiction Medicine, Journal of Dual Diagnosis, Journal of Substance Abuse Treatment, Nicotine and Tobacco Research, Preventive Medicine*

### **PUBLIC SERVICE**

Years	Service Role	
2017-Present	Vermont Psychological Services	Ph.D. Clinician

### **SUMMARY OF SERVICE ACTIVITIES**

As a post-doctoral fellow I served the Vermont Center on Behavior and Health as an organizer for the VCBH trainee seminar. During the academic year that I led the seminar, pre- and post-doctoral trainees met weekly to discuss relevant scientific articles related to behavioral pharmacology and trainee research. During the past year, I was also selected as an Executive Committee member for the, UVM Center of Biomedical Research Excellence (COBRE) at VCBH.

As part of the UVM Larner College of Medicine's preparation for the LCME Accreditation process, I was also selected by the Department Chair to serve as a member of LCME Self-Study Sub-Committee assigned to evaluate curricular management, evaluation, and enhancement.

I am currently an active member of the Association of Behavioral and Cognitive Therapists and American Psychological Association I have also been a member of The College on Problems of Drug Dependence (CPDD) since 2017, which is the oldest and largest organization dedicated to advancing the scientific study of substance use. During this time I have served CPDD as Travel Awards Committee member. Furthermore, I serve as an ad hoc reviewer for 10 journals.

Finally, I am also dedicated to clinical and scientific service. Since joining the Vermont Center on Behavioral and Health (VCBH) as a post-doctoral fellow, I have provided evidence-based treatment for mood, anxiety and trauma-related disorders through Vermont Psychological Services' outpatient training clinic. I also obtained licensure as a clinical psychologist in Vermont in 2019.

**TEACHING****FORMAL SCHEDULED COURSES**

Not applicable

**CURRICULUM DEVELOPMENT**

Not applicable

**POSTGRADUATE AND OTHER COURSES**

Year	Course Title	Course		Hours	Number of Learners	Learner Level
		R	E			
2019-Present	Trainee Journal Club, VCBH, Department of Psychiatry	x		1 weekly	8-16	Graduate and Postdoctoral
2020	First-Year Psychological Science Seminar (AS096)	x		1	40	Undergraduate

**OTHER:**

- 2015-2016 Instructor, General Psychology, University of Mississippi

**PREDOCTORAL STUDENTS SUPERVISED OR MENTORED**

Dates	Name	Program School	Role	Current Position
2019-Present	Nathaniel Moxley-Kelly	Psychological Science, University of Vermont	Ph.D. Advisor	

**DISSERTATION/THESIS COMMITTEE MEMBERSHIP**

Dates	Name	Program School	Role
2020	Alison Legrand	Psychological Science, University of Vermont	Ph.D. Dissertation Committee
2020	Ashley Dobbs	Psychological Science, University of Vermont	Ph.D. Dissertation Committee

**POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED**

Not applicable

**INFORMAL TEACHING**

Year

2019

Provided consultation on the provision of exposure-based trauma therapy to graduate clinicians working for the Vermont Correctional Addictions Program (VCAP).

**FACULTY MENTORED**

Not applicable

**OTHER VISITING FACULTY SUPERVISED**

Not applicable

**TEACHING AIDS**

Not applicable

**TEACHING AWARDS AND NOMINATIONS**

Not applicable

**SUMMARY OF TEACHING ACTIVITIES**

As discussed previously, since joining the VCBH research faculty, my role has involved training and supervising pre- and post-doctoral fellows as well as research project staff and therapists. I am also the primary research mentor for a doctoral student as part of the UVM clinical psychology doctoral program. During the past year, I was honored to serve for the first time as a member of a dissertation committee for a doctoral candidate in the clinical psychology program. As part of my post-doctoral training with Dr. Stacey Sigmon and my ongoing involvement with IBT trial, I have been fortunate to serve as a co-mentor to several pre-doctoral fellows.

In my role as a Training Mentor, I meet regularly with each trainee to discuss scholarly readings and ongoing clinical research projects. I support trainee professional development through various activities including co-authoring and co-reviewing manuscripts for peer-reviewed scientific journals and textbooks, analyzing and discussing research data, preparing data presentations for professional meetings, and providing them with opportunities to serve various professional/scientific organizations. I also continue to participate in the weekly VCBH trainee seminar. I have also authored or co-authored chapters in 2 textbooks to facilitate the dissemination of evidencebased clinical practice to students and clinicians.

Finally, as part of my secondary appointment in the Department of Psychological Sciences, I have provided consultation on the provision of exposure-based trauma therapy to graduate clinicians working for the Vermont Correctional Addictions Program (VCAP). I am also participating as a faculty panelist in an undergraduate course designed to help first-year students with their transition from high school to UVM and build community among psychology majors.

**RESEARCH AND SCHOLARLY ACTIVITIES**

---

**RESEARCH AWARDS AND GRANTS****Summary of Grant Funding History:****Ongoing Research Support**

P20GM103644-05

Peck (PI)

08/01/19-07/31/22

Agency: NIGMS

**Treating Posttraumatic Stress Disorder in Patients with Opioid Use Disorder**

The co-occurrence of opioid use disorder (OUD) and posttraumatic stress disorder (PTSD) is associated with more severe mental health symptoms and worse opioid agonist treatment (OAT) outcomes relative to either diagnosis alone. In research by our group and others, prolonged exposure therapy (PET) has been associated with reductions in PTSD symptom severity among patients receiving treatment for concomitant OUD. However, it is unclear to what extent observed improvements in PTSD symptom severity are a function of PET versus the psychopharmacological effects of OAT. This project will seek to evaluate the effects of PET above and beyond OAT for reducing PTSD symptomatology among patients with concurrent PTSD and OUD.

Role: PI

Total Period: \$487,541

RO1 DA042790

Sigmon (PI)

09/01/17-07/31/21

Agency: NIH/NIDA

**Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluation**

We have developed a novel Interim Buprenorphine Treatment that leverages pharmacotherapy, state-of-the-art technology and rigorous methodology to bridge existing delays in treatment access. In an initial R34 randomized pilot study, we demonstrated reductions in illicit opioid use and risk behaviors among waitlisted opioid abusers receiving IBT. This project will seek to replicate those highly promising initial results while simultaneously evaluating generality of our findings to additional rural settings outside our single academic medical center.

Role: Key Personnel

Total Period: \$3,715,109

Agency: Laura and John Arnold Foundation

Sigmon (PI)

08/10/17 – 01/31/21 (NCE)

**Interim Buprenorphine Treatment to reduce individual and societal harm during delays to opioid treatment: Extended duration**

We have developed a novel Interim Buprenorphine Treatment that leverages pharmacotherapy, state-of-the-art technology and rigorous methodology to bridge existing delays in treatment access. In an initial R34 randomized pilot study, we demonstrated reductions in illicit opioid use and risk behaviors among waitlisted opioid abusers receiving IBT. This project will seek to replicate those highly promising initial results while simultaneously evaluating generality of our findings to a longer treatment duration.

Role: Key Personnel

Total costs: \$776,474

Agency: Indivior, PLC

Sigmon (PI)

08/01/17 – 07/31/20

**Understanding use of opioid medications by patients and non-patients**

In this survey study we will examine individual characteristics and factors associated with illicit (non-prescribed) buprenorphine use among Vermont adults.

Role: Key Personnel

Total costs: \$235,221

T32 DA007242

Higgins (PI)

09/30/90 – 05/31/20

**Training in Behavioral Pharmacology of Drug Abuse**

This training program focuses on human behavioral pharmacology, which fills a unique niche in addiction research. Our fellows learn to identify basic behavioral and pharmacological processes underpinning addiction and to translate that knowledge into effective clinical interventions and policy.



Role: Mentor of Pre-doctoral Fellows

Total costs: \$2,815,554

### Completed Research Support

Agency: University of Mississippi  
Graduate Student Council Research Grant

Peck (PI)

04/31/16-05/01/17

#### **Factors Associated with Medication Overused Headache in Patients Seeking Treatment for Primary Headaches**

A large number of adults suffer from primary headache disorders such as migraine and tension-type headache (TTH). Many headache sufferers use acute headache medications for the treatment of headache pain and associated disability; however, the overuse of acute headache medications (>10 times/month) can paradoxically produce a progression in headache frequency in the form of medication-overuse headache (MOH). The goal of this study was to identify the variables associated with MOH in a treatment-seeking population of adults with headache so as to inform further treatment and prevention efforts.

Role: PI

Total costs: \$1,000

### Pending

Not applicable

### Selected Unfunded Grant Submissions (include scoring if available)

Not applicable

### SCHOLARSHIP

#### **Publication Summary:**

18 peer-reviewed articles

1 manuscripts currently under review

2 book chapters

### Peer Reviewed Publications

#### Original Research

1. McDermott, M. J., **Peck, K. R.**, Walters, A. B., & Smitherman, T. A. (2013). Do migraineurs selectively attend to headache-related visual stimuli? *Headache*, *53*, 356-364. (PMID: 23252468)
2. **Peck, K. R.**, Smitherman, T. A., & Baskin, S. M. (2015). Traditional and alternative treatments for depression: Implications for migraine management. *Headache*, *55*, 351-355. (PMID: 25644990)
3. Klosky, J. L., Russell, K. M., Simmons, J. L., Foster, R. H., **Peck, K. R.**, Green, D. M., & Hudson, M. M. (2015). Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer. *Pediatric Blood and Cancer*, *62*, 1630-1636. (PMID: 25900433)
4. **Peck, K. R.**, & Smitherman, T. A. (2015). Mediator variables in headache research: Methodological critique and exemplar using self-efficacy as a mediator of the relationship between headache severity and disability. *Headache*, *55*, 1102-1111. *PMID: 26247313*

5. **Peck, K. R.**, Tyc, V. L., Huang, Q., & Zhang, H. (2015). Reduction of secondhand smoke exposure in the cars of children with cancer. *Journal of Pediatric Oncology Nursing*, 32, 401-409. (PMID: 25650378)
6. Klosky, J. L., Favaro, B., **Peck, K. R.**, Simmons, J. L., Russell, K. M., Green, D. M., & Hudson, M. M. (2016). Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. *Journal of Cancer Survivorship*, 10, 449-456. (PMID: 26572902)
7. **Peck, K. R.**, Ehrentraut, J. H., & Anghelescu, D. L. (2016). Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting. *Journal of Opioid Management*, 12, 205-216. (PMID: 27435441)
8. **Peck, K. R.**, Ehrentraut, J. H., Anghelescu, D. L. (2018). Family and Peer-Group Substance Abuse as a Risk-Factor Opioid Misuse Behaviors for a Young Adult with Cancer-Related Pain – A Case Study. *Journal of Adolescent and Young Adult Oncology*, 7, 137-140. (PMID: 28910174)
9. **Peck, K.R.**, Roland, M., & Smitherman, T.A. (2018). Factors Associated with Medication-Overuse Headache in Patients Seeking Treatment for Primary Headache. *Headache*, 58, 648-660. (PMID: 29520765)
10. **Peck, K. R.**, Schumacher, J. A., Stasiewicz, P. R. & Coffey S. F. (2018). Treatment-Seeking Adults with Comorbid Posttraumatic Stress Disorder, Alcohol Use Disorder, and Opioid Use Disorder: The Effectiveness of Modified Prolonged Exposure. *Journal of Traumatic Stress*, 31, 373-382. (PMID: 29786898)
11. **Peck, K. R.**, Coffey, S. C., McGuire, A. P., Voluse, A. C., & Connolly, K. M. (2018). Cognitive Processing Therapy for Veterans Diagnosed with Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder: The Relationship between Trauma-Related Cognitions and Outcomes of a 6-week Treatment Program. *Journal of Anxiety Disorders*, 15, 34-41. (PMID: 30248534)
12. **Peck, K. R.**, Ehrentraut, J. H., Anghelescu, D. L. (2019). Provision of Adequate Pain Management to a Young Adult Oncology Patient Presenting with Aberrant Opioid-Associated Behavior – A Case Study. *Journal of Adolescent and Young Adult Oncology*, 8, 221-224. (PMID: 30335554)
13. Hollingsworth, D. W., Gauthier, J., McGuire, A. P., **Peck, K. R.**, Hahn, K., & Conolly, K. (2018). Intolerance of Uncertainty Mediates Symptoms of PTSD and Depression in African American Veterans. *Journal of Black Psychology*, 44, 667-688. doi.org/10.1177%2F0095798418809201
14. **Peck, K. R.**, Parker, M. A., & Sigmon, S. C. (2019). Reasons for non-medical use of opioids among young adults in the United States: The role of educational status. *Preventive Medicine*, 128. doi: 10.1016/j.ypmed.2019.03.047
15. **Peck, K. R.**, Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2020). Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults. *Drug and Alcohol Dependence*, 208. doi: 10.1016/j.drugalcdep.2020.107879
16. Oleskiewicz, T., Ochalek, T. A., **Peck, K. R.**, Badger, G. J., & Sigmon, S. C. (2021). Within-subject evaluation of interim buprenorphine treatment during waitlist delays. *Drug and Alcohol Dependence*, 220. doi: 10.1016/j.drugalcdep.2021.108532
17. Price, M., Albaugh, M., Hahn, S., Juliano, A. C., Fani, N., Brier, Z. M. F., Legrand, A. C., van Stolk-Cooke, K., Chaarani, B., Potter, A., **Peck, K.**, Allgaier, N., Banaschewski, T., Bokde, A. L. W., Quinlan, E. B., Desrivieres, S., Flor, H., Grigis, A., Gowland, P., Heinz, A., Ittermann, B., Martinot, J-L., Martinot, M-L. P., Artiges, E., Nees, F., Orfanos, D. P., Poustka, L., Hohmann, S., Fröhner, J. H., Smolka, M. N., Walter, H., Whelan, R., Schumann, G., Garavan, H., IMAGEN Consortium. (2021). Examination of the Association Between Exposure to Childhood Abuse and Brain Structure in Young

Adults: A Machine Learning Analysis. *Neuropsychopharmacology*. doi: 10.1038/s41386-021-00987-7

18. **Peck, K. R.**, Streck, J. M., Ochalek, T. A., & Sigmon, S. C. (2021). Examining the impact of current pain status on buprenorphine treatment response for patients with opioid use disorder. *Pain Medicine*. doi: 10.1093/pm/pnab058

### **Under Review**

1. **Peck, K.R.**, Nighbor, T., & Price, M. (submitted). Delay discounting rates in individuals with a history of opioid misuse: The additive effects of psychiatric comorbidities.

### **In Preparation**

1. Price, M., Brier, Z. M. F., Legrand, A. C., van Stolk-Cooke, K., **Peck, K.R.**, Adams, Z.W. (in preparation). The Negative Impact of Daily Media Consumption on Mental Health Symptoms During the COVID-19 Pandemic.
2. **Peck, K.R.**, Moxley-Kelly, N., & Sigmon, S.C. (in preparation). Self-Reported Posttraumatic Stress Disorder in Individuals Seeking Treatment for Opioid Use Disorder in Vermont.

### **Non-Peer Reviewed Publications**

#### **Review Articles**

Not applicable

#### **Books and Chapters**

1. **Peck, K. R.**, Johnson, Y. L., & Smitherman, T. A. (2016). Migraine. In C. Rosano, A. Ikram, & M. Ganguli (Eds.), *Neuroepidemiology (Handbook of Clinical Neurology 3<sup>rd</sup> series; Vol 138 pp. 2083-294)*. New York: Elsevier
2. Higgins S. T., Heil, S. H., & **Peck, K. R.** (in press). In D. Barlow (Ed.), *Clinical Handbook of Psychological Disorders (6<sup>th</sup> Edition)*. New York: Guilford Press.

#### **Other Scholarly Publications**

Not applicable

#### **Abstracts**

Not applicable

#### **Patents Issued or Pending**

Not applicable

#### **Other Creative Activities**

Not applicable

#### **Presentations**

#### **Regional**

1. **Peck, K. R.** (2013, July). *Parent-reported secondhand smoke exposure in the car: Trends and predictors*. Paper presented at Psychology Rounds, St. Jude Children's Research Hospital, Memphis, TN.
2. **Peck, K. R.**, Ehrentraut, J. H., & Angheliescu, D. L. (2014, July). *Aberrant opioid-associated behavior among adolescents and young adult hematology and oncology patients*. Paper presented at Psychology Rounds, St. Jude Children's Research Hospital,

Memphis, TN.

3. **Peck, K. R.** & Davis, R. E. (2015, April). *Differential effects of psychiatric comorbidities: Are female and treatment-seeking migraineurs more disabled by their pain?* Paper presented at the University of Mississippi Conference on Psychological Science, University of Mississippi, University, MS.
4. Zhao, M. S., **Peck, K. R.**, Tynes, B. L., Scott, S., & Maack, D. J. (2016, April). *Putting the E in Ew! Emotion dysregulation mediates the relation between disgust sensitivity and contamination fear.* Presented at the University of Mississippi Conference on Psychological Science, University of Mississippi, University, MS.
5. Black, A. K., **Peck, K. R.**, Hamer, J. D., Smitherman, T. A. (2016, April). *Relations among fear of pain, psychological flexibility, and headache-related disability.* Presented at the University of Mississippi Conference on Psychological Science, University, MS.
6. **Peck, K. R.** (2016, October) *Medication overuse headache.* Presented at the University of Mississippi Three Minute Thesis Competition, University, MS.
7. **Peck, K. R.** (2017, February) *Factors associated with medication-overuse headache in patients seeking treatment for primary headache.* Presented at the Annual University of Mississippi Graduate Student Council Research Symposium, University, MS.
8. **Peck, K.R.** (2018, July) *Interim buprenorphine treatment for opioid use disorder.* Presented at the annual Vermont Center on Behavior and Health Scientific Trainee Retreat, Vergennes, VT.
9. **Peck, K.R.** & Sigmon, S.C. (2019, August) *Interim buprenorphine: leveraging medication and technology to bridge the gap in treatment access.* Presented at the annual convention of the Northeast Regional IDEA Conference, Bretton Woods, NH.
10. **Peck, K.R.** (2019, October) *Posttraumatic Stress disorder in opioid dependent patients: the effects of prolonged exposure therapy.* Presented at the Vermont Center on Behavior and Health's 7th Annual COBRE Retreat, Burlington, VT.
11. **Peck, K.R.** (2020, October) *Posttraumatic Stress disorder in individuals with opioid use disorder: the effects of prolonged exposure therapy.* Presented at the Vermont Center on Behavior and Health's 8th Annual COBRE Retreat, Burlington, VT.
12. **Peck, K.R.** (2020, October) *Innovative Interventions for Rural Adults with Opioid Use Disorder.* Presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
13. **Peck, K.R.** (2020, October) *Co-occurring Posttraumatic Stress Disorder and Substance Use Disorder.* Presented at the University of Vermont Center on Rural Addiction's Community Rounds Workshop Series, Burlington, VT.

### National

1. **Peck, K.R.** (2017, June) *Pain-related anxiety and the use of acute pain medications in relation to headache frequency among individuals seeking treatment for headache.* Presented at the annual convention of the American Headache Society, Boston, MA.
2. **Peck, K.R.** (2019, August) *Examining the impact of chronic non-cancer pain on buprenorphine treatment for opioid use disorder.* Presented at the annual convention of the American Psychological Association, Chicago, IL.
3. **Peck, K.R.** (2020, June) *Treating Posttraumatic Stress Disorder in Patients with Opioid Use Disorder: Attendance-Contingent Incentives to Promote Therapeutic Gains.* Presented at the annual convention of the College on Problems of Drug Dependence.

### Poster - Regional

1. **Peck, K. R.**, Buscemi, J., Murphy, J. G., Martens, M. P. McDevitt-Murphy, M. E., Pederson, A. A., Skidmore, J. R. (2009, November). *Characteristics of college students*

- who seek help for alcohol problems*. Poster presented at the annual convention of the Tennessee Psychology Association, Nashville, TN.
2. **Peck, K. R.**, Buscemi, J., Murphy, J. G., (2010, April). *Exploration of relations between type of residence and alcohol consumption in University of Memphis students*. Poster presented at the annual University of Memphis Student Research Forum, Memphis, TN.
  3. **Peck, K. R.** (2012, August). *Center for Epidemiologic Studies Depression Scale (CES-D) and Middle-Eastern populations*. Poster presented at the annual convention of the Mississippi Psychological Association, Gulfport, MS.
  4. **Peck, K. R.** (2017, August) *Factors Associated with Medication-Overuse Headache in Patients Seeking Treatment for Primary Headache*. Poster presented at the annual Vermont Center on Behavior and Health Scientific Trainee Retreat, Vergennes, VT.
  5. Ochalek, T. A., **Peck, K. R.**, Streck, J. M., Parker, M. A., Higgins, S.T., & Sigmon, S. C. (2017, October) *Promoting smoking abstinence among patients with COPD: A novel extension of evidence-based treatment*. Poster presented at the Vermont Center on Behavior and Health's 5th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT
  6. Parker, M. A., **Peck, K. R.**, & Sigmon, S. C. (2018, October). *Reasons for non-medical use of opioids among young adults in the United States: The role of educational status*. Poster presented at the Vermont Center on Behavior and Health's 6th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  7. **Peck, K. R.**, Ochalek, T. A., Watson, C. H., Streck, J. M., & Sigmon, S. C. (2018, October). *Effects of Interim Buprenorphine Treatment for opioid use disorder for patients with pain*. Poster presented at the Vermont Center on Behavior and Health's 6th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  8. Oleskiewicz, T., Ochalek, T. A., **Peck, K. R.**, Lontine, P., Crosswhite, S., Ragaven, S., Jha, K., Grujic, A., & Sigmon, S. C. (2020, October). *Interim buprenorphine treatment (IBT): Preliminary outcomes over a longer duration*. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  9. Ragaven, S. S., Jha, K., **Peck, K. R.**, & Sigmon, S. C. (2020, October). *Where are the black, indigenous, and people of color (BIPOC) in the rural opioid epidemic? Examining treatment needs in Vermont*. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.
  10. Moxley-Kelly, N., Badger, G., Cole, R., & **Peck, K.R.** (2020, October). *Using attendance-based monetary incentives to increase attendance to prolonged exposure therapy sessions in individuals with concurrent OUD and PTSD*. Poster presented at the Vermont Center on Behavior and Health's 8th Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT.

### **Poster - National**

1. Buscemi, J., Murphy, J. G., Martens, M. P., McDevitt-Murphy, M. E., Pederson, A. A., Skidmore, J. R., & **Peck, K. R.** (2009, November). *Help-seeking for alcohol use in college students: Correlates and preferred methods*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Addictive Behaviors SIG, New York, NY.
2. Peck, K. R., Nicholson, J., & Tyc, V. L. (2013, April). *Parent-reported exposure to second-hand smoke in motor vehicles for children on treatment for cancer*. Poster presented at the National Conference in Pediatric Psychology, New Orleans, LA.

3. Davis, R. E., **Peck, K. R.**, Hamer, J. D., & Smitherman, T. A. (2013, June). *Relations between alcohol use and migraine among young adults*. Poster presented at the annual convention of the American Headache Society, Boston, MA.
4. **Peck, K. R.**, Moynahan, V. L., & Smitherman, T. A. (2013, November). *Relationships between self-efficacy, headache diagnosis, and impairment*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
5. **Peck, K. R.**, Nicholson, J., & Tyc, V. L. (2013, November). *Mediation and moderation of secondhand smoke exposure (SHSe): The role of self-efficacy (SE) and perceived vulnerability in parents of pediatric cancer patients*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
6. **Peck, K. R.**, Zhao, M. S., & Smitherman, T. A. (2015, June). *Gender and its interaction with depressive symptoms as predictors of disability in chronic migraine*. Poster presented at the annual convention of the American Headache Society, Washington, DC.
7. Ochalek, T. A., **Peck, K. R.**, Badger, G. J., & Sigmon, S. C. (2018, May). *Within-subject evaluation of interim buprenorphine treatment during waitlist delays*. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Diego, CA.
8. **Peck, K. R.**, Ochalek, T. A., Badger, G. J., & Sigmon, S. C. (2018, May). *Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults*. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Diego, CA.
9. **Peck, K. R.**, Ochalek T.A., Watson, C. H., Streck, J. M., & Sigmon, S. C. (2018, November). *Effects of Interim Buprenorphine Treatment for opioid use disorder for patients with pain*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Washington, DC.
10. **Peck, K. R.**, Ochalek, T. A., Watson, C. H., & Sigmon, S. C. (2019, June). *Examining the impact of chronic non-cancer pain on buprenorphine treatment response for individuals with opioid use disorder*. Poster presented at the annual convention of the College on Problems of Drug Dependence, San Antonio, TX.
11. **Peck, K. R.**, Parker, M. A., & Sigmon, S. C. (2019, November). *Reasons for non-medical use of prescription opioids among young adults: Role of educational status*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies, Atlanta, GA.
12. **Peck, K. R.**, Nighbor, T. N., & Price, M. (2020, June). *Impulsivity in Individuals with a History of Opioid Use with and without Posttraumatic Stress Disorder versus Healthy Controls*. Poster presented at the annual convention of the College on Problems of Drug Dependence.
13. Oleskowitz, T. N., Ochalek, T. A., **Peck, K. R.**, Badger, G., Wiley, R. C., & Sigmon, S. C. (2020, June). *Interim buprenorphine treatment: Preliminary outcomes with a longer duration*. Poster presented at the annual convention of the College on Problems of Drug Dependence.
14. Wiley, R. C., Oleskowitz, T. N., Ochalek, T. A., **Peck, K. R.**, & Sigmon, S. C. (2020, June). *Cocaine use and urinary cotinine during Interim Buprenorphine Treatment*. Poster presented at the annual convention of the College on Problems of Drug Dependence.
15. **Peck, K. R.**, Pagan, D., Klemperer, K., Badger, G., & Sigmon, S. C. (2020, November). *Prolonged Exposure for Treating PTSD Among Individuals Receiving Methadone or Buprenorphine for Opioid Use Disorder*. Poster presented at the annual convention of the Association of Behavioral and Cognitive Therapies.

### **Poster - International**

1. Ehrentraut, J. H., Jurbergs, N., **Peck, K. R.**, Canavera, K., & Willard, T. (2013, October). *Treatment acceptability of a brief, single-session workshop for families of children with chronic pain*. Poster presented at the International Forum on Pediatric Pain, Nova Scotia, Canada.

## **INVITED PRESENTATIONS**

### **Regional**

1. **Peck, K.R.** (2018, October) The Ongoing Opioid Epidemic: Barriers to Treatment, Novel Treatment Approaches, and Vulnerable Populations. Invited educational talk presented at the Fairfield University Department of Psychology, Fairfield, CT.
2. **Peck, K. R.**, Klemperer, E. (2020, February). Co-occurring Opioid Use and Mental Health Disorders. Presented to the Chittenden County Opioid Alliance as part of the monthly CommunityStat meeting, Burlington, VT.

### **Invited Media Interviews**

1. December 2015. UM programs target stress for students for finals. Invited interview with The Daily Mississippian.
2. February 2020. This woman's research saves lives: Meet the director of UVM's Center on Rural Addiction. Invited interview with The Daily Cynic.

## **Quality Improvement and Patient Safety Activities**

## **SUMMARY OF SCHOLARLY ACTIVITIES**

My research and clinical interests are two-fold. First, I am conducting research focused on the development and evaluation of novel treatments for opioid misuse and use disorder. Second, I have worked extensively with individuals with concurrent substance use disorders and posttraumatic stress disorder (PTSD), particularly around the delivery and evaluation of cognitive-behavioral treatments for PTSD.

I have engaged in programmatic research aimed at developing and evaluating cognitive-behavioral treatments for PTSD for individuals with co-occurring substance use disorders. This research includes a study demonstrating the efficacy of a behavioral treatment for PTSD among individuals who engaged in problematic drinking and opioid misuse, as well as cognitive-behavioral interventions for individuals with co-occurring PTSD and substance use disorders. As part of the same treatment program, we also demonstrated that intolerance of uncertainty mediated the relationship between certain PTSD symptoms depression symptoms among African American veterans. More recently, my research has focused on the co-occurrence of OUD and PTSD. This work has included an examination of the role of impulsivity in individuals with OUD and PTSD. Taken together, my work has provided strong support for the efficacy of cognitive-behavioral PTSD treatments among individuals with co-occurring substance use disorders as well as an improved understanding of their mechanisms of action.

More recently, I have worked closely with my mentor, Dr. Stacey Sigmon, to conduct two large randomized clinical trials evaluating a novel interim buprenorphine treatment (IBT) for reducing illicit opioid use and other high-risk behaviors among individuals with untreated OUD. While those primary trials are still underway, our group has already begun submitting a steady stream of manuscripts for publication. Most recently, our group has evaluated the

efficacy of IBT among young adults, as well as the underlying reasons for non-medical use of prescription opioids among young adults, using a nationally-representative sample of 941 US adults aged 18-25. Our work has also included a within-subject evaluation of IBT effectiveness, and an investigation of chronic pain status as a moderator of opioid treatment outcomes.

I also have clinical and research expertise in the treatment of adolescents and young adults who misuse opioids, specifically those who have been diagnosed with cancer. I published several case studies illustrating an interdisciplinary multimodal treatment approach that was developed to provide adequate pain management while simultaneously minimizing the risk of aberrant opioid-associated behaviors among pediatric oncology patients. These studies were written with the goal of bringing the issue of opioid misuse to the attention of anesthesiologists and oncologists who frequently treat adolescents and young adults with disease- and treatment-related cancer pain. In addition, I published the first comprehensive review of risk factors for opioid misuse among adolescent and young adult oncology patients. Overall, these reports are among the first to address the risk of opioid misuse in pediatric patients with cancer and offer some of the only recommendations for treatment available to treatment providers who work with this population.

Finally, I have research and clinical expertise in the treatment of individuals with migraine and other headache conditions. This experience has included investigations of pain-related attentional biases in this challenging clinical population, as well as psychiatric comorbidities among patients with migraine, with a specific emphasis on the clinical implications of co-occurring depression. I published a methodological paper demonstrating a contemporary, theory-driven, and statistically rigorous approach to mediation analyses as applied to headache. More recently, I completed a University of Mississippi Graduate Student Council-funded research grant applying machine learning to identify risk factors associated with medication overuse in a sample of adults seeking treatment for primary headache disorders in rural Mississippi. The peer-reviewed scientific journal *Headache* subsequently published the results of this study, and *Neurology Advisor* featured it in its coverage of impactful headache research (March 30, 2018).

Overall, since joining the faculty in 2019, I have been the Primary Investigator on this R21-equivalent project that is funded through a larger COBRE P20 award. I am also currently coordinating two randomized clinical trials evaluating a novel interim buprenorphine treatment for reducing illicit opioid use and other high-risk behaviors among adults with untreated OUD. I have published 18 manuscripts in peer-reviewed scientific journals and two book chapters. Since joining the VCBH research faculty, my role has involved training and supervising pre- and post-doctoral fellows as well as research project staff and therapists. I am the primary research mentor for a doctoral student as part of the UVM clinical psychology doctoral program. During the past year, I was also honored to serve for the first time as a member of a dissertation committee for a doctoral candidate in the clinical psychology program. I present my research at numerous regional and national peer-reviewed scientific meetings annually and have been invited to present my work (Fairfield University Department of Psychology and the Chittenden County Opioid Alliance). I have provided continuous service to the department, college and College on Problems of Drug Dependence.